Bensheng Ju1, Wenbiao Chen2, Brent A Orr3, Jan M Spitsbergen4, Sujuan Jia5, Christopher J Eden6, Hannah E Henson7,8, Michael R Taylor9,10. 1. Department of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA. bensheng.ju@stjude.org. 2. Department of Molecular Physiology & Biophysics, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA. wenbiao.chen@vanderbilt.edu. 3. Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, 38105, USA. brent.orr@stjude.org. 4. Fish Disease Research Group, Department of Microbiology, Oregon State University, Corvallis, OR, 97331, USA. spitsbej@onid.orst.edu. 5. Department of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA. sujuan.jia@stjude.org. 6. Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA. ceden@nikon.net. 7. Department of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA. hannah.henson@uky.edu. 8. Integrated Program in Biomedical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA. hannah.henson@uky.edu. 9. Department of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA. michael.taylor@wisc.edu. 10. Current address: Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA. michael.taylor@wisc.edu.
Abstract
BACKGROUND: Zebrafish have been used as a vertebrate model to study human cancers such as melanoma, rhabdomyosarcoma, liver cancer, and leukemia as well as for high-throughput screening of small molecules of therapeutic value. However, they are just emerging as a model for human brain tumors, which are among the most devastating and difficult to treat. In this study, we evaluated zebrafish as a brain tumor model by overexpressing a human version of oncogenic KRAS (KRAS(G12V)). METHODS: Using zebrafish cytokeratin 5 (krt5) and glial fibrillary acidic protein (gfap) gene promoters, we activated Ras signaling in the zebrafish central nervous system (CNS) through transient and stable transgenic overexpression. Immunohistochemical analyses were performed to identify activated pathways in the resulting brain tumors. The effects of the MEK inhibitor U0126 on oncogenic KRAS were evaluated. RESULTS: We demonstrated that transient transgenic expression of KRAS(G12V) in putative neural stem and/or progenitor cells induced brain tumorigenesis. When expressed under the control of the krt5 gene promoter, KRAS(G12V) induced brain tumors in ventricular zones (VZ) at low frequency. The majority of other tumors were composed mostly of spindle and epithelioid cells, reminiscent of malignant peripheral nerve sheath tumors (MPNSTs). In contrast, when expressed under the control of the gfap gene promoter, KRAS(G12V) induced brain tumors in both VZs and brain parenchyma at higher frequency. Immunohistochemical analyses indicated prominent activation of the canonical RAS-RAF-ERK pathway, variable activation of the mTOR pathway, but no activation of the PI3K-AKT pathway. In a krt5-derived stable and inducible transgenic line, expression of oncogenic KRAS resulted in skin hyperplasia, and the MEK inhibitor U0126 effectively suppressed this pro-proliferative effects. In a gfap-derived stable and inducible line, expression of oncogenic KRAS led to significantly increased mitotic index in the spinal cord. CONCLUSIONS: Our studies demonstrate that zebrafish could be explored to study cellular origins and molecular mechanisms of brain tumorigenesis and could also be used as a platform for studying human oncogene function and for discovering oncogenic RAS inhibitors.
BACKGROUND:Zebrafish have been used as a vertebrate model to study humancancers such as melanoma, rhabdomyosarcoma, liver cancer, and leukemia as well as for high-throughput screening of small molecules of therapeutic value. However, they are just emerging as a model for humanbrain tumors, which are among the most devastating and difficult to treat. In this study, we evaluated zebrafish as a brain tumor model by overexpressing a human version of oncogenic KRAS (KRAS(G12V)). METHODS: Using zebrafishcytokeratin 5 (krt5) and glial fibrillary acidic protein (gfap) gene promoters, we activated Ras signaling in the zebrafish central nervous system (CNS) through transient and stable transgenic overexpression. Immunohistochemical analyses were performed to identify activated pathways in the resulting brain tumors. The effects of the MEK inhibitor U0126 on oncogenic KRAS were evaluated. RESULTS: We demonstrated that transient transgenic expression of KRAS(G12V) in putative neural stem and/or progenitor cells induced brain tumorigenesis. When expressed under the control of the krt5 gene promoter, KRAS(G12V) induced brain tumors in ventricular zones (VZ) at low frequency. The majority of other tumors were composed mostly of spindle and epithelioid cells, reminiscent of malignant peripheral nerve sheath tumors (MPNSTs). In contrast, when expressed under the control of the gfap gene promoter, KRAS(G12V) induced brain tumors in both VZs and brain parenchyma at higher frequency. Immunohistochemical analyses indicated prominent activation of the canonical RAS-RAF-ERK pathway, variable activation of the mTOR pathway, but no activation of the PI3K-AKT pathway. In a krt5-derived stable and inducible transgenic line, expression of oncogenic KRAS resulted in skin hyperplasia, and the MEK inhibitor U0126 effectively suppressed this pro-proliferative effects. In a gfap-derived stable and inducible line, expression of oncogenic KRAS led to significantly increased mitotic index in the spinal cord. CONCLUSIONS: Our studies demonstrate that zebrafish could be explored to study cellular origins and molecular mechanisms of brain tumorigenesis and could also be used as a platform for studying human oncogene function and for discovering oncogenic RAS inhibitors.
Authors: Michelle Monje; Siddhartha S Mitra; Morgan E Freret; Tal B Raveh; James Kim; Marilyn Masek; Joanne L Attema; Gordon Li; Terri Haddix; Michael S B Edwards; Paul G Fisher; Irving L Weissman; David H Rowitch; Hannes Vogel; Albert J Wong; Philip A Beachy Journal: Proc Natl Acad Sci U S A Date: 2011-03-01 Impact factor: 11.205
Authors: Lene Uhrbom; Chengkai Dai; Joseph C Celestino; Marc K Rosenblum; Gregory N Fuller; Eric C Holland Journal: Cancer Res Date: 2002-10-01 Impact factor: 12.701
Authors: Ty W Abel; Cara Clark; Brian Bierie; Anna Chytil; Mary Aakre; Agnieszka Gorska; Harold L Moses Journal: Mol Cancer Res Date: 2009-05-12 Impact factor: 5.852
Authors: Anh Tuan Nguyen; Alexander Emelyanov; Chor Hui Vivien Koh; Jan M Spitsbergen; Serguei Parinov; Zhiyuan Gong Journal: Dis Model Mech Date: 2011-09-08 Impact factor: 5.758
Authors: Uswa Shahzad; Michael S Taccone; Sachin A Kumar; Hidehiro Okura; Stacey Krumholtz; Joji Ishida; Coco Mine; Kyle Gouveia; Julia Edgar; Christian Smith; Madeline Hayes; Xi Huang; W Brent Derry; Michael D Taylor; James T Rutka Journal: Neuro Oncol Date: 2021-05-05 Impact factor: 12.300
Authors: Marie Mayrhofer; Victor Gourain; Markus Reischl; Pierre Affaticati; Arnim Jenett; Jean-Stephane Joly; Matteo Benelli; Francesca Demichelis; Pietro Luigi Poliani; Dirk Sieger; Marina Mione Journal: Dis Model Mech Date: 2016-11-24 Impact factor: 5.758
Authors: Ernest Dodoo; Markus Maeurer; Zhenjiang Liu; Martin Rao; Thomas Poiret; Silvia Nava; Qingda Meng; Anna von Landenberg; Jiri Bartek; Shanshan Xie; Georges Sinclair; Inti Peredo Journal: Oncotarget Date: 2017-08-16